Grail (NASDAQ: GRAL), a developer of multi-cancer early detection tests, has seen its stock price plummet following disappointing clinical trial results.

The company, which spun off from Illumina in June 2024, now faces questions about its contrarian investment potential.

>>> The Online Era Is Pushing Screen Romantics to Alarming Extremes

Shares opened at $13.95 after the spin-off and reached an all-time high of $116.06 on January 22, 2026.

However, the stock has since fallen to around $60 after a major single-day collapse in February.

The decline was triggered by unfavorable results from the largest NHS England trial evaluating Grail's flagship blood test, Galleri.

The trial failed to meet its primary clinical endpoint, prompting analysts to revise their outlook.

Canaccord Genuity lowered its Street-high price target from $105 to $80 per share.

Despite the reduction, the new target implies a potential upside of over 30% from current trading levels, leaving contrarian investors debating whether to buy the dip.

>>> Apple TV+ Launches Twisty Thriller “Maximum Pleasure Guaranteed”

Galleri Test and Regulatory Hurdles

The Galleri blood test aims to detect signals for dozens of cancers before symptoms appear.

It seeks to consolidate multiple traditional screenings, such as mammograms and colonoscopies, into a single blood draw.

The FDA granted Galleri a Breakthrough Device designation in 2019 to accelerate regulatory review. However, the official Premarket Approval (PMA) submission has not yet received clearance.

Without full FDA approval, commercial distribution is limited to out-of-pocket transactions ranging from $749 to $949 per test.

Current buyers include affluent clients, some corporate employers, hospital pilots, and telehealth networks.

>>> George Lucas on Star Wars Prequel Fights and Parenting Wisdom

Financial Performance and Projections

Grail increased its revenue from $93 million in 2023 to $147 million in 2025. During the same period, net losses narrowed from $1.47 billion to $408 million.

Market estimates project revenue to climb 25% to $224 million in 2027, though net losses are expected to widen to $485 million.

Forecasts for 2028 anticipate a 27% revenue increase to $285 million, with a net loss of $481 million.

Grail maintains a market capitalization of $2.56 billion, which values the equity at 14 times its projected sales for this year.

Long-term commercial expansion depends heavily on private insurance coverage, Medicare integration, and eventual FDA approval.

For contrarian investors, the key question is whether the recent decline presents a buying opportunity or signals deeper problems.

>>> US Crude Oil Futures Drop Below April Peak as Inventories Rise

The company's revenue growth and narrowing losses are positive signs, but regulatory and market constraints remain significant.